A Review Article on Novel Antifungal Agents with Different Heterocyclic Nucleus

The health of immunosuppressed individuals worldwide is greatly affected by the widespread and increasing burden of fungal infections. The emergence of resistant species like Candida auris and Aspergillus fumigatus have highlighted the limitations of conventional antifungal agents, including azoles, polyenes, and echinocandins. New agents with different heterocyclic nuclei have emerged from the discovery of new antifungal drugs, resulting in improved pharmacological profiles and unique mechanisms of action. A groundbreaking new treatment for vulvovaginal candidiasis is Ibrexafungerp, the first oral triterpenoid-glucan synthases inhibitor. For candidemia, echinocandin, also known as rezafungin (long-acting antibiotic), provides convenient once-weekly dosing. A targeted approach to prevent recurrent cases of vulvovaginal candidiasis is provided by the next-generation tetrazole, Otesconazole. Both Fosmanogepix and pyrimidine biosynthesis inhibit Gwt1, with the latter being an antifungal, and both are effective against rare molds and resistant strains. In addition, treatments such as isavuconazole (Cresemba), micafungin and posaconozole continue to expand.'. Heterocyclic scaffolds are considered promising antifungal innovations, with emphasis on their structural properties, mechanisms, efficacy, and safety. The advancement of research in clinical evaluation and heterocyclic chemistry is expected to enhance the antifungal potential, while also addressing existing therapeutic gaps in treating both invasive and resistant fungal infections.